| Literature DB >> 20098612 |
Takayuki Ogi1, Palupi Margiastuti, Toshiaki Teruya, Junsei Taira, Kiyotake Suenaga, Katsuhiro Ueda.
Abstract
A series of new C(11) cyclopentenones 1-7 was isolated, together with four known metabolites 9/10, 12 and 13, from the extract of the didemnid ascidian Lissoclinum sp. The other didemnid ascidian Diplosoma sp. contained didemnenones 1, 2 and 5, and five known metabolites 8-12. The structures of 1-7 were elucidated by spectroscopic analyses. Cytotoxicity of the isolated compounds was evaluated against three human cancer cell lines (HCT116, A431 and A549).Entities:
Keywords: Diplosoma; Lissoclinum; cyclopentenone; cytotoxicity; didemnenone
Mesh:
Substances:
Year: 2009 PMID: 20098612 PMCID: PMC2810228 DOI: 10.3390/md7040816
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1.Some C11 metabolites isolated from marine organisms.
Figure 2.Compounds isolated from two didemnid ascidians.
1H-NMR data for compounds 1–6.
| 1a | 3.74 (dd, 6.0, 11.2) | 3.68 (dd, 6.2, 10.8) | 3.53 (d, 11.4) | 3.49 (d, 11.2) | 4.26 (d, 11.2) | 4.27 (d, 11.4) |
| 1b | 3.51 (dd, 6.0, 11.2) | 3.49 (dd, 6.2, 10.8) | 3.42 (d, 11.4) | 3.43 (d, 11.2) | 4.13 (d, 11.2) | 3.50 (d, 11.4) |
| 3 | 7.35 (d, 6.0) | 7.35 (d, 6.2) | 7.52 (d, 5.6) | 7.52 (d, 5.6) | 7.71 (d, 5.6) | 3.99 (brt, 4.8) |
| 4a | 6.25 (d, 6.0) | 6.27 (d, 6.2) | 6.28 (d, 5.6) | 6.30 (d, 5.6) | 6.40 (d, 5.6) | 2.74 (dd, 4.8, 18.4) |
| 4b | 1.98 (brd, 18.4) | |||||
| 6 | 3.45 (s) | 3.48 (s) | 3.74 (s) | |||
| 8 | 7.73 (dd, 1.6, 16.0) | 6.91 (d, 16.0) | 6.48 (d, 11.2) | 6.45 (brd, 10.8) | 7.22 (d, 11.6) | 7.27 (dd, 1.4, 16.0) |
| 9 | 6.43 (dq, 16.0, 6.8) | 6.43 (dq, 16.0, 5.8) | 6.58 (ddd, 11.2, | 6.59 (ddd, 10.4, | 6.86 (ddd, 10.0, | 6.31 (dq, 16.0, 6.8) |
| 11.6, 16.4) | 10.8, 16.4) | 11.6, 16.8) | ||||
| 10a | 1.83 (dd, 1.6, 6.8) | 1.85 (d, 5.8) | 5.38 (d, 16.4) | 5.40 (brd, 2.0, 16.4) | 5.85 (dd, 1.6, 10.0) | 1.82 (dd, 1.4, 6.8) |
| 10b | 5.23 (d, 11.6) | 5.26 (brd, 2.0, 10.0) | 5.67 (dd, 1.6, 16.8) | |||
| 11a | 4.64 (dd, 6.8, 13.4) | 4.82 (dd, 5.6, 11.2) | 5.10 (brd, 5.8) | 4.82 (s) | 5.51 (d, 5.4) | |
| 11b | 4.36 (dd, 6.8, 13.4) | 4.59 (dd, 5.6, 11.2) | ||||
| OH-1 | 4.89 (t, 6.0) | 4.84 (t, 6.2) | ||||
| OH-2 | 5.72 (s) | 5.73 (s) | 5.87 (s) | 5.94 (s) | 6.33 (brs) | 5.24 (s) |
| OH-3 | 5.14 (brd, 4.8) | |||||
| OH-11 | 4.66 (brs) | 4.53 (t, 5.6) | 6.73 (d, 5.8) | 6.59 (d, 5.4) | ||
| OCH3 | 3.31 (s) | |||||
Recorded at 400 MHz in DMSO-d6.
13C-NMR data for compounds 1–6.
| 1 | 66.8 (CH2) | 66.3 (CH2) | 63.2 (CH2) | 63.1 (CH2) | 69.7 (CH2) | 63.1 (CH2) |
| 2 | 80.5 (qC) | 80.4 (qC) | 79.7 (qC) | 79.2 (qC) | 75.8 (qC) | 73.0 (qC) |
| 3 | 161.4 (CH) | 161.4 (CH) | 165.1 (CH) | 165.1 (CH) | 164.9 (CH) | 70.5 (CH) |
| 4 | 134.3 (CH) | 135.1 (CH) | 132.8 (CH) | 132.8 (CH) | 134.2 (CH) | 46.3 (CH2) |
| 5 | 197.1 (qC) | 196.9 (qC) | 203.8 (qC) | 203.6 (qC) | 202.9 (qC) | 206.1 (qC) |
| 6 | 133.5 (qC) | 134.0 (qC) | 55.5 (CH) | 55.1 (CH) | 53.5 (CH) | 130.4 (qC) |
| 7 | 144.5 (qC) | 144.9 (qC) | 135.0 (qC) | 132.4 (qC) | 122.7 (qC) | 142.3 (qC) |
| 8 | 127.2 (CH) | 128.6 (CH) | 131.7 (CH) | 132.4 (CH) | 143.1 (CH) | 124.4 (CH) |
| 9 | 134.8 (CH) | 134.7 (CH) | 132.3 (CH) | 132.1 (CH) | 132.0 (CH) | 135.3 (CH) |
| 10 | 19.1 (CH3) | 19.4 (CH3) | 119.9 (CH2) | 120.5 (CH2) | 128.0 (CH2) | 19.1 (CH3) |
| 11 | 56.6 (CH2) | 54.0 (CH2) | 91.7 (CH) | 98.7 (CH) | 166.9 (qC) | 86.6 (CH) |
| OCH3 | 54.9 (CH3) | |||||
Recorded at 100 MHz in DMSO-d.
Figure 3.Partial structures of 1 and 2 based on COSY (bold line) and some important HMBC–correlations (arrows).
Figure 4.Selected NOEs for 1 and 2.
NMR data (DMSO-d6) for compound 7.
| 1 | 63.3 (CH2) | 3.53 (brd, 8.0) | 2, 3, 6, 11 | 1′a | 66.6 (CH2) | 3.70 (dd, 6.0, 10.8) | 6′, 3′, 2′ |
| 2 | 79.1 (qC) | 1′b | 3.46 (dd, 6.0, 10.8) | 6′, 3′, 2′ | |||
| 3 | 165.1 (CH) | 7.55 (d, 5.6) | 1, 2, 4, 5, 6, | 2′ | 80.4 (qC) | ||
| 4 | 132.8 (CH) | 6.31 (d, 5.6) | 2, 3, 5, 6 | 3′ | 161.6 (CH) | 7.37 (d, 6.0) | 6′, 5′, 3′, 2′ |
| 5 | 203.6 (qC) | 4′ | 134.9 (CH) | 6.28 (d, 6.0) | 6′, 5′, 3′, 2′ | ||
| 6 | 55.1 (CH) | 3.48 (s) | 2, 3, 4, 5, 7, 8 | 5′ | 196.7 (qC) | ||
| 7 | 132.6 (qC) | 6′ | 135.2 (qC) | ||||
| 8 | 132.8 (CH) | 6.37 (d, 10.0) | 6, 7, 9, 10, 11 | 7′ | 140.7 (qC) | ||
| 9 | 132.2 (CH) | 6.59 (ddd, 10.0, 10.0, 17.2) | 8 | 8′ | 126.9 (CH) | 7.78 (dd, 1.4, 16.0) | 11′, 7′, 10′ |
| 10a | 120.3 (CH2) | 5.30 (d, 17.2) | 8, 9 | 9′ | 134.7 (CH) | 6.41 (m) | 8′, 10′ |
| 10b | 5.26 (d, 10.0) | 8, 9 | 10′ | 19.1 (CH3) | 1.88 (dd, 1.4, 6.8) | 8′, 9′ | |
| 11 | 97.9 (CH) | 5.08 (s) | 1, 7, 8, 11′ | 11′a | 62.7 (CH2) | 4.86 (d, 10.4) | 11, 7′, 6′, 8′ |
| OH-2 | 5.95 (s) | 1, 2, 3, 6 | 11′b | 4.49 (d, 10.4) | 11, 7′, 6′, 8′ | ||
| OH-1′ | 4.93 (t, 6.0) | 1′, 2′ | |||||
| OH-2′ | 5.80 (s) | 6′, 2′, 1′ | |||||
Recorded at 100 MHz;
Recorded at 400 MHz.
Figure 5.Compounds used for determining the absolute structure of 8.
Cytotoxic activity of compounds 1–13.
| 3.2 | 6.1 | 6.4 | |
| 3.0 | 6.4 | 4.8 | |
| 5.2 | 7.5 | >20 | |
| 4.7 | 6.6 | 11.1 | |
| 2.3 | 3.9 | >20 | |
| 6.8 | 15.3 | 15.9 | |
| 2.8 | 9.4 | 12.8 | |
| 1.8 | 3.1 | 3.5 | |
| 3.1 | 3.6 | >20 | |
| >20 | >20 | >20 | |
| 2.4 | 3.3 | >20 | |
| 7.2 | >20 | >20 | |
HCT116: human colorectal carcinoma;
A431: human epidermal carcinoma;
A549: human lung cancer.
Scheme 1.Plausible biosynthesis of the carbon skeletons for didemnenones and related compounds.